LegoChem Biosciences has announced the Company was awarded U.S. Patent No. 14517616, entitled “Antibody-Active Agent Conjugates and Methods of Use.”
The patent illustrates the company’s ConjuAllTM technology, LegoChem’s proprietary ADC platform which enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells. This patent provides LegoChem comprehensive coverage in the United States for its ADC platform technology.
“This patent further strengthens LCB’s competitive advantage in the field of research and development of next generation ADCs,” Dr. Yeong Soo Oh, Senior Vice President & Chief Technology Officer of LCB said. “The use of our technology will address significant unmet needs of current ADC technologies.”